|Videos|October 17, 2017

What is the First-line Empiric Therapy for Candidemia?

Author(s)Contagion&reg Editorial Staff

Monica Mahoney, PharmD, BCPS-AQ ID, explains the first-line empiric therapy for candidemia.

Monica Mahoney, PharmD, BCPS-AQ ID, clinical pharmacy coordinator of infectious diseases at Beth Israel Deaconess Medical Center, discusses the changes the Infectious Diseases Society of America made in their candidemia guidelines. Now, regardless of immunocompromised status, IDSA recommends echinocandins as the first-line therapy for candidemia. Dr. Mahoney also explains potential reasons why this change was made.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Subscribe Now!

What is the First-line Empiric Therapy for Candidemia?

Newsletter

Related Content

Top Infectious Disease News Stories Week of December 20 - December 26

Optimism After Open-Label Study as Rising Carbapenem Resistance Shapes Future Treatment Guidance

Top Infectious Disease News Stories Week of December 13 - December 19

Emory Healthcare: Melding Critical Care, Infectious Diseases, and Disaster Preparedness Together

Aztreonam-Avibactam Demonstrates Noninferior Cure Rates and Strong Safety Profile Compared With Meropenem/Colistin

Latest CME

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arizona

2nd Annual Hawaii Cancer Conference

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

(CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

(COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Addressing Unmet Needs in HER2+ Metastatic BTC

Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

The Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

(COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

29th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Community Practice Connections™: 21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

22nd Annual Winter Lung Cancer Conference®

10th Annual School of Gastrointestinal Oncology

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

(CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

(COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Collaborative Care Symposium

Proactive Adverse Event Management for HER2+ BTC Treatments

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

(COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

17th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics and Beyond

(COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

10th Annual Live Medical Crossfire®: Hematologic Malignancies

25th Annual International Congress on the Future of Breast Cancer® East

Southern California Psychiatry Conference

27th Annual International Lung Cancer Congress®

Southern Florida Psychiatry Conference

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Minnesota

Advancements in Chronic Myeloid Leukemia: Treatment Strategies, Mechanisms, and Patient Management

‘REEL’ Time Patient Counseling™: Improving Quality of Life for Patients with Sickle Cell Disease – Disease Modifying Therapy Vs. Curative Approaches

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Practical Approaches to Modern Dry Eye Treatment and Management

(CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

(CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

(CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

(CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

(COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?